NeuroSense Therapeutics Ltd. (NRSN) Ownership
NRSN ownership summary
as of October 17, 2026- Institutions
- 1.0% of shares outstanding
- Insiders
- 31.42% of shares outstanding
- Shares outstanding
- 1.9M
- Float
- 1.2M shares available to trade
- Short interest
- 1.80% 27K shares short
- Days to cover
- 0.88 short interest down 29.7% vs prior month
- Institutions 1.05%
- Insiders 31.42%
- Other investors 67.53%
NRSN top institutional holders
16 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | UBS Group AG | 0.29% | 109K | $333,513 | +59,540 (+121.3%) | June 30, 2026 |
| 2 | Independent Advisor Alliance | 0.26% | 100K | $307,000 | +50,000 (+100.0%) | June 30, 2026 |
| 3 | Yorkville Advisors Global, LP | 0.21% | 78K | $239,460 | — | June 30, 2026 |
| 4 | Commonwealth Equity Services, LLC | 0.06% | 23K | $69,919 | — | June 30, 2026 |
| 5 | PNC Financial Services Group Inc | 0.06% | 21K | $64,930 | — | June 30, 2026 |
| 6 | Pathstone Holdings LLC | 0.04% | 17K | $50,741 | — | June 30, 2026 |
| 7 | Geode Capital Management, LLC | 0.04% | 16K | $48,721 | — | June 30, 2026 |
| 8 | XTX Topco Ltd | 0.03% | 11K | $35,222 | +11,473 (0.0%) | June 30, 2026 |
| 9 | Creative Planning Inc | 0.03% | 11K | $35,029 | −501 (−4.2%) | June 30, 2026 |
| 10 | HRT FINANCIAL LLC | 0.03% | 11K | $32,281 | +10,515 (0.0%) | June 30, 2026 |
| 11 | JONES FINANCIAL COMPANIES LLLP | <0.01% | 1,000 | $3,070 | — | June 30, 2026 |
| 12 | SBI Securities Co Ltd | <0.01% | 255 | $783 | −10 (−3.8%) | June 30, 2026 |
| 13 | Meitav Dash Investments Ltd | 0.00% | — | — | −40,000 (−100.0%) | June 30, 2026 |
| 14 | Jane Street Group LLC | 0.00% | — | — | −28,670 (−100.0%) | June 30, 2026 |
| 15 | Two Sigma Investments LLC | 0.00% | — | — | −44,445 (−100.0%) | June 30, 2026 |
| 16 | Squarepoint Ops LLC | 0.00% | — | — | −17,926 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 16, 4 holders added 132K shares and 6 cut 132K.
NRSN top mutual fund and ETF holders
1 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index | 0.04% | 16K | $48,721 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
NRSN shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns NRSN
Institutional investors own 1.0% of NeuroSense Therapeutics's shares and insiders 31.42%. The largest holder is UBS Group AG with 0.29% of the shares (109K), as of June 30, 2026. Among the top 16 institutions, 4 added shares and 6 reduced their stake in the latest filings. Short interest is 1.80% of the float, or 0.88 days of average trading volume. The share count fell 74.4% since 2019.
Related: NRSN analyst forecast, NRSN key metrics. See the NRSN stock overview for the latest quote and news.
NRSN ownership FAQ
Who owns the most NeuroSense Therapeutics stock?
The largest shareholders of NeuroSense Therapeutics are UBS Group AG (0.29%), Independent Advisor Alliance (0.26%), Yorkville Advisors Global, LP (0.21%), Commonwealth Equity Services, LLC (0.06%), PNC Financial Services Group Inc (0.06%).
What percentage of NeuroSense Therapeutics is owned by institutions?
Institutions hold 1.0% of NeuroSense Therapeutics's shares outstanding; insiders hold 31.42%.
Which funds own NeuroSense Therapeutics?
The largest fund holders of NeuroSense Therapeutics are Fidelity Nasdaq Composite Index (0.04%).
What is NeuroSense Therapeutics's short interest?
27K shares of NeuroSense Therapeutics were sold short, 1.80% of the float; at the average daily volume it would take 0.88 days to cover.
How many shares of NeuroSense Therapeutics are outstanding?
NeuroSense Therapeutics has 1.9M shares outstanding, of which 1.2M are in the public float.